Selection and Qualification of Simplified QSP Models When Using Model Order Reduction Techniques
- 288 Downloads
Quantitative systems pharmacology (QSP) models are increasingly used in drug development to provide a deep understanding of the mechanism of action of drugs and to identify appropriate disease targets. Such models are, however, not suitable for estimation purposes due to their high dimensionality. Based on any desired and specific input-output relationship, the system may be reduced to a model with fewer states and parameters. However, any simplification process will be a trade-off between model performance and complexity. In this study, we develop a weighted composite criterion which brings together the opposing indices of performance and dimensionality. The weighting factor can be determined by qualification of the simplified model based on a visual predictive check (VPC) using the precision of each parameter. The weighted criterion and model qualification techniques were illustrated with three examples: a simple compartmental pharmacokinetic model, a physiologically based pharmacokinetic (PBPK) example, and a semimechanistic model for bone mineral density. When considering the PBPK example, this automated search identified the same reduced model which had been detected in a previous report, as well as a simpler model which had not been previously identified. The simpler bone mineral density model provided an adequate description of the response even after 1 year from the initiation of treatment. The proposed criterion together with a VPC provides a natural way for model order reduction that can be fully automated and applied to multiscale models.
KEY WORDScomposite criterion proper lumping scale reduction systems models visual predictive check
Compliance with Ethical Standards
Conflict of Interest
Chihiro Hasegawa is an employee of Ono Pharmaceutical Co., Ltd. and a visiting researcher at the University of Otago.
- 2.Benson N, Matsuura T, Smirnov S, Demin O, Jones HM, Dua P, et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus. 2013;3(2):20120071. https://doi.org/10.1098/rsfs.2012.0071.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Peters E, Heuberger JAAC, Tiessen R, van Elsas A, Masereeuw R, Arend J, et al. Pharmacokinetic modeling and dose selection in a randomized, double-blind, placebo-controlled trial of a human recombinant alkaline phosphatase in healthy volunteers. Clin Pharmacokinet. 2016;55(10):1227–37. https://doi.org/10.1007/s40262-016-0399-y.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Bauer RJ. NONMEM users guide introduction to NONMEM 7.3.0. Hanover: ICON Development Solutions; 2013.Google Scholar
- 15.Pan S, Duffull S. Automated proper lumping for simplification of systems models. Hersonissos, Crete: Population Approach Group Europe PAGE; 2015.Google Scholar
- 21.Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;2(7):e51. https://doi.org/10.1038/psp.2013.26.CrossRefPubMedGoogle Scholar
- 25.Demin O, Karelina T, Svetlichniy D, Metelkin E, Speshilov G, Demin O Jr, et al. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst Pharmacol. 2013;2(9):e74. https://doi.org/10.1038/psp.2013.49.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Hasegawa C, Duffull SB. Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations. J Pharmacokinet Pharmacodyn. 2017. https://doi.org/10.1007/s10928-017-9527-z.
- 27.Zheng J, van Schaick E, LS W, Jacqmin P, Perez Ruixo JJ. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data. J Pharmacokinet Pharmacodyn. 2015;42(4):333–47. https://doi.org/10.1007/s10928-015-9422-4.CrossRefPubMedGoogle Scholar
- 29.Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res. 1990;5(4):311–9. https://doi.org/10.1002/jbmr.5650050402.CrossRefPubMedGoogle Scholar